FierceBiotechOriginal article
{"a":[{"_":"FDA plans to release more drug rejection letters as controversial policy resumes","$":{"href":"/biotech/fda-plans-release-more-drug-rejection-letters-controversial-policy-resumes","hreflang":"en"}}]}
RegulatoryNegative
AI Analysis
Summary
The FDA has confirmed resumption of its controversial policy to publicly release drug rejection letters, which had been paused in April 2026. The agency plans to release additional rejection documents in the future.
Outcome Details
FDA resuming policy to publicly release drug rejection letters after pause in April 2026
Importance:4/10
Sentiment:
-0.30
FDA policydrug rejectionstransparencyregulatory
Read the original article
Published by FierceBiotech on July 14, 2026 2:19 PM